Table 4 Overview of the biodistribution of 223Ra after intravenous injection in patients from four clinical trials [8, 10, 11, 17] in comparison to the modelled data of the present work; data expressed as percentage of administered 223Ra; values given as range, median or mean ± SD; n = patient number
Region | Time post-injection | Present work | Nilsson et al. [17] n = 25 | Carrasquillo et al. [11] n = 10 | Chittenden et al. [10] n = 6 | Yoshida et al. [8] n = 6 |
|---|---|---|---|---|---|---|
Plasma | 10-15 min | 55 | 12 | 9-28 (22) | ||
4 h | 2.0 | 1.6-3.9 (2) | 1-6 (4) | |||
24 h | 0.5 | < 1 | 0.37-1.0 (0.55) | 0.6-5.1 (1.1) | ||
3 d | 0.2 | 0-0.9 (0.3) | ||||
Bonea | 2 h | 28.2 | 41-57 (52) | |||
4 h | 29.8 | 61 ± 10 | ||||
Urine (cumulative) | 4 h | 0.83 | 5 (first void) | |||
2 d | 1.58 | 2 ± 2 | 2 | |||
Faeces (cumulative) | 1 d | 12.9 | 40-61 (52) | |||
2 d | 35.3 | 13 ± 12 | ||||
3 d | 47.4 | 29-95 (64) | ||||
7 d | 52.1 | 60-80 | ||||
RC/ULI* content | 1 d | 11.6 | 45 ± 16 | |||
7 d | 0.53 | 0-18 (4) | ||||
LC/LLI** content | 2 d | 7.4 | 17 ± 11 | |||
7 d | 0.64 | 6 ± 4 | ||||
HATM/GI tract*** content | 6 h | 40.9 | 22-85 (64) | |||
1 d | 39.3 | 50.8 ± 7.5 | 32-78 (52) | |||
2 d | 22.0 | 4-76 (31) | ||||
3 d | 11.8 | 5-53 (21) | ||||
7-8 d | 1.9 | 0-9 (3) |